Whats up everyone, so in this video we are going back to the biotech sector,
to share with you insights on a small penny stock, which is developing some novel gene
therapy to disrupt a disease which hits very close to home – and that’s cancer and diabetes.
And whilst there are many catalysts at play here, one of the major ones is that, the U.S. FDA
launched an initiative that aims to expedite the development of gene therapies for patients with
rare diseases. As such, the FDA announced that it will support using biomarkers as substitutes
for other biological indicators in gene therapy clinical trials, accelerating the approval process
for companies. So what this really means is that, this is a very positive development for this penny
stock as the FDA streamlines the regulatory process to help bring much needed therapies
to patients more efficiently. This decision by the FDA also underscores the potential
role of gene therapy to provide long-lasting and even curative treatments for diseases that are
currently difficult to manage or are untreatable. So make sure you stick around to find out from
their CEO himself on why this opportunity could be one for your watchlist. But here’s what you
need to aware about the gene therapy sector before we jump into the details of the stock.
The global gene therapy market was valued at $2.9 billion (US) in 2021 and is expected to
reach over $15.68 billion (US) by 2030, and that’s a growth at a CAGR of 20.2% from 2022 to 2030.
Gene therapy is described as the treatment of an illness by changing, replacing, or supplementing
a missing or defective genetic combination that is responsible for the disease. And gene therapy has
become one of the most desirable research goals in the fight against degenerative illnesses.
The need for gene therapy is being driven by an increase in the number of cases of cancer and
other chronic diseases all across the world. They are designed to treat diseases by altering genetic
information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a
healthy copy of the gene. This form of treatment could have the potential to cure diseases such
as diabetes, cancer, heart disease, and AIDS, which is going to be game changing.
So make sure you stick around to find out whether this gem deserves a place on your
watchlist or not as I’m sure you’d want to pay attention to its story.
And with that out of the way, please drop a quick like on the video and hit the bell,
so we can get talking about Genprex Inc (GNPX) which is now sitting at 86cents per share with
a market cap of $44.7mn. Genprex has had a good last month in the markets bouncing
from its lows of 76cents per share and now sitting up 13% in the last month.
But on a ytd basis, it is still down 45%, which is a tough position to be in. But yet again when
you think about the current environment we operate in with high inflation, increasing interest rate
and the many macro factors impacting the stock markets, then I feel it would be naïve to write
off stocks like this, without scratching the surface. And this is because when you
dig just a little deeper, you begin to realise what an opportunity could be unearthed with
this gem, when you get to connect to their management focus and their long term plans.
So as we always aim to buy low and sell high, these rock bottom prices are presenting decent
entry points for those who believe in their story, some excellent entry points for those
with high risk appetites, to maximise the upside opportunity from this gem..
So here’s the latest on Genprex which you need to be aware of.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing
therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer
disease-fighting genes, to provide new therapies for large patient populations with cancer and
diabetes, who currently have limited treatment options. They work with world-class institutions
and collaborators, to develop drug candidates to further their pipeline of gene therapies,
in order to provide novel treatment approaches. Their oncology program utilizes its proprietary,
non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the
first systemic gene therapy delivery platform used for cancer in humans.
The Company’s lead product candidate, REQORSA™, is being evaluated as a treatment for non-small cell
lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from
the FDA which you can see here, which is just a huge boost for them and their R&D pipeline timing.
But before we go any further let’s hear from their CEO & Chairman, Rodney Varner, to help bring to
life what the company does, their portfolio & what investors can look out for in the months ahead.
Wow, some really great prospects to look out for.
Genprex also Received a Safety Review Committee Approval to Advance their
Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso®
in Advanced Non-Small Cell Lung Cancer. The combination of REQORSA and osimertinib
received the FDAs Fast Track Designation for treatment of the Acclaim-1 patient population.
Genprex also recently Published Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical
Trial for their lead product REQORSA. They are encouraged by the favorable safety profile of
REQORSA, as well as the preliminary efficacy data observed, and they believe this data
will support their advancement to the Phase 2 portion of the clinical trial.
Analysts at Seeking Alpha Genprex's Gene Therapy has a Potential Breakthrough For Diabetes And
Lung Cancer. They said the company’s diabetes gene therapy exhibited encouraging preclinical results,
improving glucose tolerance and reducing insulin requirements.
The GPX-002/003 gene therapy could be a long-lasting solution for diabetes,
potentially benefiting many patients who require insulin replacement
therapy. The company's lead therapy candidate, Reqorsa, has received FDA fast-track designation
as a combination therapy with Tagrisso. They also had a strong financial position
with zero debt and a cash balance of $29.52 million as of September 2022.
Robert LeBoyer is a Senior Equity Research Analyst with over 16 years of industry
experience on Biotech and Pharmaceuticals joined Noble Capital Markets in 2021.
LeBoyer reiterated a $5.00 target on Genprex, Inc. (Nasdaq: GNPX) after the company announced
its Phase 1/2 Acclaim-1 trial in non-small cell lung cancer giving an indication on how
bullish they are on the prospects of this stock. And from the current price levels,
that’s a staggering 5.8X from current levels which is just massive.
So some very very interesting insights worth considering for Genprex but only
consider getting in if the price is right for you and if you fully understand the risks.
This video is not financial advice, a buy or a sell recommendation, but is meant to bring some
new and exciting biotech stocks to your attention for you to do your own research.. As always I
would love to hear from you, so please let me know your thoughts on these top lithium stocks
in the comments section below and what other biotech stocks are catching your eyes lately.
And If you are new to my channel, please ensure to subscribe and hit the bell so you are notified
when I upload new videos. If you would like to see more videos like this, please check out this
video right here or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video. Thank you